arrow
N

Nicolas Mach

University of Geneva
H指数:34
被引数:8,115

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study

顺铂和nab-紫杉醇加压腹腔内气溶胶化疗(PIPAC)在腹膜癌病患者的安全性和有效性:Nab-PIPAC 1b期研究

2026-09-010
OAAI
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 Trial

Ib期临床试验:Copanlisib联合Venetoclax治疗复发或难治性B细胞非霍奇金淋巴瘤——SAKK 66/18试验

Cancers
IF4.4
2026-05-280
OAAI
Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – a multicenter single arm open label phase II trial (SAKK 15/19)

胸腺放射治疗联合Durvalumab维持治疗,在一线Carboplatin和Etoposide联合Durvalumab治疗后的广泛期小细胞肺癌(ES-SCLC)——一项多中心单臂开放标签II期临床试验(SAKK 15/19)。

2025-11-290
OAAI
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025-09-300
OAAI
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

接受MVX-ONCO-1(一种新型、首创的细胞包封基免疫疗法)治疗的复发性/转移性头颈部鳞状细胞癌患者,在经过≥1线系统性治疗后进展的总体生存率:SAKK 11/16期IIa临床试验结果

2025-09-010
OAAI
Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle

胸腺放射治疗联合durvalumab维持治疗在一线卡铂和依托泊苷联合durvalumab治疗后的广泛期小细胞肺癌(ED-SCLC)中的应用:一项多中心单臂开放标签II期试验(SAKK 15/19)。

2024-09-010
PRE
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
2024-06-0111
PRE
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

帕博利珠单抗与甲氨蝶呤,多西他赛或西妥昔单抗在复发或转移性头颈部鳞状细胞癌中的比较 (KEYNOTE-040): 疾病复发模式的亚组分析

2023-12-014
OAAI
SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
2023-10-012
OA
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
2023-10-013
OAAI
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients
2023-07-262
OAAI
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
2022-07-064
OAAI